Bioluminescence Imaging Reveals Dynamics of Beta Cell Loss in the Non-Obese Diabetic (NOD) Mouse Model

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Virostko, John ^a   Radhika, Armandla ^b   Poffenberger, Greg ^b   Dula, Adrienne N ^a   Moore, Daniel J ^b   Powers, Alvin C ^b,c,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

AGE DISTRIBUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BIOLUMINESCENCE; CAMERA; CELL FUNCTION; CELL LOSS; CELL SIZE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HYPERGLYCEMIA; IMAGE ANALYSIS; IMAGING SYSTEM; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULITIS; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS; PANCREAS ISLET BETA CELL; TARGET CELL;

AGING; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FEMALE; GENETIC HETEROGENEITY; HYPERGLYCEMIA; IMAGING, THREE-DIMENSIONAL; INSULIN-SECRETING CELLS; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 84874599329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057784     Document Type: Article

References (34)

1. Kikutani H, Makino S, (1992) The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 51: 285-322.
2. Haskins K, McDuffie M, (1990) Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 249: 1433-1436.
3. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, et al. (1993) Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366: 72-75.
4. Anderson MS, Bluestone JA, (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23: 447-485.
5. Klinke DJ 2nd (2008) Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 3: e1374.
6. Pozzilli P, Signore A, Williams AJ, Beales PE, (1993) NOD mouse colonies around the world-recent facts and figures. Immunol Today 14: 193-196.
7. Atkinson MA, Eisenbarth GS, (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221-229.
8. Ize-Ludlow D, Lightfoot YL, Parker M, Xue S, Wasserfall C, et al. (2011) Progressive erosion of beta-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes. Diabetes 60: 2086-2091.
9. Melanitou E, Devendra D, Liu E, Miao D, Eisenbarth GS, (2004) Early and quantal (by litter) expression of insulin autoantibodies in the nonobese diabetic mice predict early diabetes onset. J Immunol 173: 6603-6610.
10. Abiru N, Yu L, Miao D, Maniatis AK, Liu E, et al. (2001) Transient insulin autoantibody expression independent of development of diabetes: comparison of NOD and NOR strains. J Autoimmun 17: 1-6.
11. Andre I, Gonzalez A, Wang B, Katz J, Benoist C, et al. (1996) Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A 93: 2260-2263.
12. Andralojc K, Srinivas M, Brom M, Joosten L, de Vries IJ, et al. (2012) Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis. Diabetologia 55: 1247-1257.
13. Virostko J, Powers AC, (2009) Molecular imaging of the pancreas in small animal models. Gastroenterology 136: 407-409.
14. Park SY, Wang X, Chen Z, Powers AC, Magnuson MA, et al. (2005) Optical imaging of pancreatic beta cells in living mice expressing a mouse insulin I promoter-firefly luciferase transgene. Genesis 43: 80-86.
15. Smith SJ, Zhang H, Clermont AO, Powers AC, Kaufman DB, et al. (2006) In vivo monitoring of pancreatic beta-cells in a transgenic mouse model. Mol Imaging 5: 65-75.
16. Virostko J, Henske J, Vinet L, Lamprianou S, Dai C, et al. (2011) Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands. Proc Natl Acad Sci U S A 108: 20719-20724.
17. Virostko J, Radhika A, Poffenberger G, Chen Z, Brissova M, et al. (2010) Bioluminescence imaging in mouse models quantifies beta cell mass in the pancreas and after islet transplantation. Mol Imaging Biol 12: 42-53.
18. Wong GT, (2002) Speed congenics: applications for transgenic and knock-out mouse strains. Neuropeptides 36: 230-236.
19. Fowler M, Virostko J, Chen Z, Poffenberger G, Radhika A, et al. (2005) Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging. Transplantation 79: 768-776.
20. Virostko J, Chen Z, Fowler M, Poffenberger G, Powers AC, et al. (2004) Factors influencing quantification of in vivo bioluminescence imaging: application to assessment of pancreatic islet transplants. Mol Imaging 3: 333-342.
21. Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, et al. (2006) Pancreatic islet production of vascular endothelial growth factor-a is essential for islet vascularization, revascularization, and function. Diabetes 55: 2974-2985.
22. Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, et al. (2005) Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 53: 1087-1097.
23. Angstetra E, Graham KL, Emmett S, Dudek NL, Darwiche R, et al. (2009) In vivo effects of cytokines on pancreatic beta-cells in models of type I diabetes dependent on CD4(+) T lymphocytes. Immunol Cell Biol 87: 178-185.
24. Kloppel G, Drenck CR, Oberholzer M, Heitz PU, (1984) Morphometric Evidence for a Striking B-Cell Reduction at the Clinical Onset of Type-1 Diabetes. Virchows Archiv a-Pathological Anatomy and Histopathology 403: 441-452.
25. Bonner-Weir S, Trent DF, Weir GC, (1983) Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71: 1544-1553.
26. Sever D, Eldor R, Sadoun G, Amior L, Dubois D, et al. (2011) Evaluation of impaired beta-cell function in nonobese-diabetic (NOD) mouse model using bioluminescence imaging. Faseb J 25: 676-684.
27. Baxter AG, Mandel TE, (1991) Accelerated diabetes in non-obese diabetic (NOD) mice differing in incidence of spontaneous disease. Clin Exp Immunol 85: 464-468.
28. Williams AJ, Krug J, Lampeter EF, Mansfield K, Beales PE, et al. (1990) Raised temperature reduces the incidence of diabetes in the NOD mouse. Diabetologia 33: 635-637.
29. Elliott RB, Reddy SN, Bibby NJ, Kida K, (1988) Dietary prevention of diabetes in the non-obese diabetic mouse. Diabetologia 31: 62-64.
30. Oldstone MB, (1988) Prevention of type I diabetes in nonobese diabetic mice by virus infection. Science 239: 500-502.
31. Fu W, Wojtkiewicz G, Weissleder R, Benoist C, Mathis D, (2012) Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol 13: 361-368.
32. Chatenoud L, Thervet E, Primo J, Bach JF, (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 91: 123-127.
33. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608.
34. Atkinson MA, Leiter EH, (1999) The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5: 601-604.